000127604 001__ 127604
000127604 005__ 20240228135030.0
000127604 0247_ $$2doi$$a10.1186/1748-717X-9-113
000127604 0247_ $$2pmid$$apmid:24886574
000127604 0247_ $$2pmc$$apmc:PMC4030022
000127604 0247_ $$2altmetric$$aaltmetric:2349471
000127604 037__ $$aDKFZ-2017-03627
000127604 041__ $$aeng
000127604 082__ $$a610
000127604 1001_ $$0P:(DE-HGF)0$$aKoerber, Stefan Alexander$$b0$$eFirst author
000127604 245__ $$aEfficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.
000127604 260__ $$aLondon$$bBioMed Central$$c2014
000127604 3367_ $$2DRIVER$$aarticle
000127604 3367_ $$2DataCite$$aOutput Types/Journal article
000127604 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1506584694_13931
000127604 3367_ $$2BibTeX$$aARTICLE
000127604 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127604 3367_ $$00$$2EndNote$$aJournal Article
000127604 520__ $$aConcurrent chemotherapy and radiation therapy is the preferred standard of care for patients with anal cancer. Several studies have suggested a benefit of intensity-modulated radiation therapy (IMRT) compared with 3D-conformal radiation (3D-CRT) regarding acute toxicity. This study evaluates outcome and toxicity of patients undergoing IMRT/Tomotherapy or 3D-CRT at our institution.A cohort of 105 anal cancer patients was treated with chemoradiation or radiation alone (16.2%) between January 2000 and December 2011. 37 patients received 3D-CRT while 68 patients were treated with IMRT. Follow-up exams were performed every 3 to 6 months for a minimum of 3 years and then annually.Median follow-up was 41.4 months (2.8 - 158.4). Overall survival (OS), Progression-free survival (PFS) and local control (LC) at 3 years was 70.3%, 66.5%, 78.3% in the 3D-CRT group and 82.9%, 66.5%, 75.3% in the IMRT group without statistically significant difference. 3-year Colostomy-free survival (CFS) was 85.7% in the IMRT/Tomotherapy group and 91.8% in the 3D-CRT group (p = 0.48). No grade 4 toxicity was found in both groups. Severe (G2/3) acute skin toxicity (94.6% vs. 63.2%; p < 0.001) and acute gastrointestinal toxicity rate (67.6% vs. 47.1%; p = 0.03) was significantly higher with 3D-CRT compared to IMRT/Tomotherapy.The use of IMRT can reduce acute severe side effects of the skin and gastrointestinal tract but did not demonstrate improved results regarding OS, PFS, LC and CFS.
000127604 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000127604 588__ $$aDataset connected to CrossRef, PubMed,
000127604 7001_ $$0P:(DE-He78)4169c43af2de6fae487c89fc2e7cfaa8$$aSlynko, Alla$$b1$$udkfz
000127604 7001_ $$aHaefner, Matthias F$$b2
000127604 7001_ $$aKrug, David$$b3
000127604 7001_ $$aSchoneweg, Clara$$b4
000127604 7001_ $$aKessel, Kerstin$$b5
000127604 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b6$$udkfz
000127604 7001_ $$aHerfarth, Klaus$$b7
000127604 7001_ $$0P:(DE-HGF)0$$aDebus, Juergen$$b8
000127604 7001_ $$0P:(DE-He78)75d45845a04db67c5a88db1086046ef1$$aSterzing, Florian$$b9$$eLast author$$udkfz
000127604 773__ $$0PERI:(DE-600)2224965-5$$a10.1186/1748-717X-9-113$$gVol. 9, no. 1, p. 113 -$$n1$$p113 $$tRadiation oncology$$v9$$x1748-717X$$y2014
000127604 909CO $$ooai:inrepo02.dkfz.de:127604$$pVDB
000127604 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000127604 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4169c43af2de6fae487c89fc2e7cfaa8$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000127604 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000127604 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000127604 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)75d45845a04db67c5a88db1086046ef1$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000127604 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000127604 9141_ $$y2014
000127604 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127604 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127604 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127604 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000127604 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000127604 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000127604 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000127604 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000127604 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127604 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127604 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127604 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000127604 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000127604 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lKKE Strahlentherapie$$x1
000127604 980__ $$ajournal
000127604 980__ $$aVDB
000127604 980__ $$aI:(DE-He78)C060-20160331
000127604 980__ $$aI:(DE-He78)E050-20160331
000127604 980__ $$aUNRESTRICTED